Anadys - it's research focus neatly split - raised $38.3 million in its Series C round in what could be its last financing before testing the investment waters with an initial public offering. (BioWorld Today)
Schering-Plough Corp. acquired exclusive rights to two human antibodies derived from Human Genome Sciences Inc.'s technology, thereby completing HGS's obligations to Schering as defined by the Human Gene Therapeutic Consortium. (BioWorld Today)
Schering-Plough Corp. acquired exclusive rights to two human antibodies derived from Human Genome Sciences Inc.'s technology, thereby completing HGS's obligations to Schering as defined by the Human Gene Therapeutic Consortium. (BioWorld Today)
